Skip to content
COYA·Nasdaq·US

Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (Tregs) for the treatment of neurodegenerative, autoimmune, and metabolic diseases. It has expertise in three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, with its lead candidate COYA 302 in clinical development for ALS and FTD.

Source: SEC 10-K Mar 16, 2026

Thematic Position

COYA

Relationship Groups

Suppliers1
Competitors16

Relationship details are part of the Pro plan.

Ended Relationships

2 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

state aidpricing regulation
Affordable Care Act pricing, rebate and 340B provisions affect pharmaceutical pricing
SEC 10-KMar 16, 2026

The full regulatory passage is part of the Pro plan.